Oxytocin in survivors of childhood-onset craniopharyngioma

Anna M M Daubenbüchel, Anika Hoffmann, Maria Eveslage, Jale Özyurt, Kristin Lohle, Julia Reichel, Christiane M Thiel, Henri Martens, Vincent Geenen, Hermann L Müller, Anna M M Daubenbüchel, Anika Hoffmann, Maria Eveslage, Jale Özyurt, Kristin Lohle, Julia Reichel, Christiane M Thiel, Henri Martens, Vincent Geenen, Hermann L Müller

Abstract

Quality of survival of childhood-onset craniopharyngioma patients is frequently impaired by hypothalamic involvement or surgical lesions sequelae such as obesity and neuropsychological deficits. Oxytocin, a peptide hormone produced in the hypothalamus and secreted by posterior pituitary gland, plays a major role in regulation of behavior and body composition. In a cross-sectional study, oxytocin saliva concentrations were analyzed in 34 long-term craniopharyngioma survivors with and without hypothalamic involvement or treatment-related damage, recruited in the German Childhood Craniopharyngioma Registry, and in 73 healthy controls, attending the Craniopharyngioma Support Group Meeting 2014. Oxytocin was measured in saliva of craniopharyngioma patients and controls before and after standardized breakfast and associations with gender, body mass index, hypothalamic involvement, diabetes insipidus, and irradiation were analyzed. Patients with preoperative hypothalamic involvement showed similar oxytocin levels compared to patients without hypothalamic involvement and controls. However, patients with surgical hypothalamic lesions grade 1 (anterior hypothalamic area) presented with lower levels (p = 0.017) of oxytocin under fasting condition compared to patients with surgical lesion of posterior hypothalamic areas (grade 2) and patients without hypothalamic lesions (grade 0). Craniopharyngioma patients' changes in oxytocin levels before and after breakfast correlated (p = 0.02) with their body mass index. Craniopharyngioma patients continue to secrete oxytocin, especially when anterior hypothalamic areas are not involved or damaged, but oxytocin shows less variation due to nutrition. Oxytocin supplementation should be explored as a therapeutic option in craniopharyngioma patients with hypothalamic obesity and/or behavioral pathologies due to lesions of specific anterior hypothalamic areas. Clinical trial number: KRANIOPHARYNGEOM 2000/2007(NCT00258453; NCT01272622).

Keywords: Behavior; Craniopharyngioma; Hypothalamus; Obesity; Oxytocin.

References

    1. Endocrinology. 2013 Feb;154(2):589-96
    1. Biol Psychol. 2013 Feb;92(2):179-84
    1. Obes Rev. 2012 Sep;13(9):780-98
    1. Obesity (Silver Spring). 2015 May;23(5):950-6
    1. Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):81-9
    1. Front Hum Neurosci. 2015 Mar 17;9:132
    1. Diabetes. 2013 Oct;62(10):3418-25
    1. Nature. 2002 Jul 4;418(6893):85-9
    1. Eur J Clin Nutr. 1991 Jan;45(1):13-21
    1. Eur J Endocrinol. 2006 Mar;154(3):483-9
    1. Endocr Rev. 2014 Jun;35(3):513-43
    1. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E134-44
    1. Neuron. 2010 Mar 25;65(6):768-79
    1. Psychoneuroendocrinology. 2013 Sep;38(9):1883-94
    1. Rev Endocr Metab Disord. 2013 Dec;14(4):311-29
    1. Peptides. 1991 Jan-Feb;12(1):113-8
    1. Trends Neurosci. 2012 Nov;35(11):649-59
    1. J Clin Endocrinol Metab. 2014 Dec;99(12):4683-9
    1. Neuron. 2011 Feb 10;69(3):523-35
    1. Front Endocrinol (Lausanne). 2015 Oct 15;6:160
    1. Clin Chem Lab Med. 2006;44(4):358-65
    1. Horm Behav. 2012 Mar;61(3):392-9
    1. Scand J Clin Lab Invest. 2001;61(5):407-15
    1. Front Neurosci. 2015 Sep 24;9:335
    1. Neuroendocrinology. 2003 Oct;78(4):185-203
    1. Neuroscience. 1989;32(2):435-9
    1. Horm Res Paediatr. 2010;74(1):62-6
    1. Behav Neurosci. 2015 Aug;129(4):389-98
    1. Drug Discov Today Dis Mech. 2013 Jun 1;10(1-2):e63-e68
    1. J Clin Endocrinol Metab. 2012 Nov;97(11):3935-43
    1. J Clin Endocrinol Metab. 2011 Jul;96(7):1981-91
    1. Neuro Oncol. 2015 Jul;17(7):1029-38
    1. Nature. 2006 Sep 21;443(7109):289-95
    1. Orphanet J Rare Dis. 2011 Jun 24;6:47
    1. Front Neuroendocrinol. 2009 Oct;30(4):534-47
    1. Eur J Pharmacol. 2008 Apr 7;583(2-3):226-42
    1. Eur J Endocrinol. 2011 Jul;165(1):17-24
    1. J Pediatr Endocrinol Metab. 2016 Aug 1;29(8):995-1000
    1. Neurosci Biobehav Rev. 2013 Sep;37(8):1485-92
    1. Prog Neurobiol. 2009 Jun;88(2):127-51
    1. J Clin Endocrinol Metab. 1954 Jan;14(1):13-31

Source: PubMed

3
Předplatit